How do you pay?

How to pay the least

Ask for the cash price

Danziten

We didn’t find one.

  1. Ask your pharmacy for Danziten’s cash price, and one or two other pharmacies too.
  2. Danziten’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameDanziten
Authorized genericnilotinib
Regular genericnilotinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Danziten?
The original
–
–

Brand nameThe maker’s card

Danziten CONNECT Co-Pay Program

Savings card from Azurity Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on activatethecard.com 

See the offer on danziten.com

In the maker’s words

“Commercially insured eligible patients may pay as low as $0 each monthb…”

From the maker’s offer on danziten.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Danziten itself, from the same company, sold without the brand name, and usually for less. For now Danziten is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.

Source: the FDA label for Danziten (Azurity Pharmaceuticals, Inc.), July 28, 2025. Full label on DailyMed 

Good to know